SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that its Chief Science Officer, Dr. Richard H. Tullis presented a clinical report on the Aethlon Hemopurifier® to Nephrologists attending the International Conference on Dialysis on January 29th. The focal point of Dr. Tullis’s presentation was the use of the Hemopurifier® to manage disease progression in end-stage renal disease (ESRD) patients infected with viral pathogens, including Hepatitis-C (HCV) and Human Immunodeficiency Virus (HIV). Aethlon anticipates Nephrologists will become early adopters of the Hemopurifier® as viral infection significantly increases patient mortality in ESRD patients who require regular dialysis treatment.
